FDA approves first CAR T-cell therapy for adults with leukemia or lymphoma
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed ...
Mar 19, 2024
0
3